Shaperon (XKRX:378800) Change In Receivables : ₩-318.86 Mil (TTM As of Mar. 2025)

View and export this data going back to 2022. Start your Free Trial

What is Shaperon Change In Receivables?

Shaperon's change in receivables for the quarter that ended in Mar. 2025 was ₩-6.56 Mil. It means Shaperon's Accounts Receivable increased by ₩6.56 Mil from Dec. 2024 to Mar. 2025 .

Shaperon's change in receivables for the fiscal year that ended in Dec. 2024 was ₩-505.24 Mil. It means Shaperon's Accounts Receivable increased by ₩505.24 Mil from Dec. 2023 to Dec. 2024 .

Shaperon's Accounts Receivable for the quarter that ended in Mar. 2025 was ₩0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Shaperon's Days Sales Outstanding for the three months ended in Mar. 2025 was 0.00.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Shaperon's liquidation value for the three months ended in Mar. 2025 was ₩8,705.43 Mil.

Shaperon Change In Receivables Historical Data

The historical data trend for Shaperon's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shaperon Change In Receivables Chart

Shaperon Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Change In Receivables

Get a 7-Day Free Trial

86.42

-13.45

13.45

-505.24

Shaperon Quarterly Data
	Dec19	Dec20	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Change In Receivables	Get a 7-Day Free Trial											-192.94	123.34	-89.77	-345.86	-6.56

Shaperon Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-318.86 Mil.

Shaperon (XKRX:378800) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Shaperon's Days Sales Outstanding for the quarter that ended in Mar. 2025 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	11.803	*	91
=	0.00

2. In Ben Graham's calculation of liquidation value, Shaperon's accounts receivable are only considered to be worth 75% of book value:

Shaperon's liquidation value for the quarter that ended in Mar. 2025 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	11306.917	-	2664.822	+	0.75 * 0	+	0.5 * 126.67
=	8,705.43

Shaperon Change In Receivables Related Terms

Thank you for viewing the detailed overview of Shaperon's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Shaperon Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shaperon Inc (XKRX:378800) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

Gangnam Ace Tower G9, Suie 218 & 606, 174-10 Jagok-ro, Gangnam-gu, Seoul, KOR, 06373

Website

http://www.shaperon.com

Shaperon Inc is a developer of innovative inflammasome inhibitors and nanobody therapeutics intended to develop novel treatments for various chronic inflammatory diseases, including atopic dermatitis, systemic inflammatory response syndrome, neuroinflammatory diseases, and chronic inflammation. It offers a range of drug candidates, including a gel-type atopic dermatitis drug for use in the treatment of systemic inflammatory response syndrome, neuroinflammatory diseases and for treating chronic inflammation. The company also provides immunotherapeutic products and a single-domain neutralizing antibody, enabling clients to improve patient's quality of life by developing safe and efficacious drugs and immunotherapies.

Shaperon Headlines

No Headlines